NCT05249972View on ClinicalTrials.gov

A Phase III Study in Subjects With Mild to Moderate Psoriasis.

PHASE3UnknownINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

August 11, 2022

Study Completion Date

August 18, 2022

Conditions
Mild to Moderate Psoriasis
Interventions
DRUG

AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)

Topical cutaneous spray

DRUG

Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)

Topical foam

OTHER

Placebo

Placebo cutaneous spray

Trial Locations (1)

Unknown

RECRUITING

Lotus Multispeciality Hospital, Ahmedabad

Sponsors

Lead Sponsor

Lipidor AB
All Listed Sponsors
lead

Lipidor AB

INDUSTRY

NCT05249972 - A Phase III Study in Subjects With Mild to Moderate Psoriasis. | Biotech Hunter | Biotech Hunter